DFTX:NASDAQ
Definium Therapeutics Inc
$28.58
arrow_downward
-1.85%(-0.54) 1D
Nov 19, 12:08:32 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DFTX...
Open
$29.44
High
$29.98
Low
$28.23
Mkt. cap
3.91B
Avg. vol.
1.74M
Volume
661.13K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.02
Beta
2.23
Shares outstanding
136.90M
No. of employees
106
Open
$29.44
High
$29.98
Low
$28.23
Mkt. cap
3.91B
Avg. vol.
1.74M
Volume
661.13K
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.02
Beta
2.23
Shares outstanding
136.90M
No. of employees
106
News stories
From web sources and news partners
TradingView
·
2 days ago
DFTX: DT120 targets a one-to-three-dose model, with an H1 2027 NDA plan and a 2027 MDD readout
Yahoo Finance Australia
·
2 days ago
Definium Therapeutics, Inc. (DFTX) Seasonal returns chart
Yahoo Finance
·
1 week ago
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitedefiniumtx.com
Analyst ratings
Based on 14 analysts giving stock ratings to DFTX in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for DFTX in the last 3 months.
Highest
Current $28.58
$91.00 (+218.40%)
Average
$75.07 (+162.67%)
Lowest
$55.00 (+92.44%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tessa Romero J.P. Morgan | Buy | Reiterated | $85.00 | +197.4% | 11/17/2026 |
Brian Abrahams RBC Capital | Buy | Maintained | $70.00 | +144.9% | 11/16/2026 |
Justin Walsh JonesTrading | Buy | Reiterated | $90.00 | +214.9% | 11/12/2026 |
Michael Okunewitch Maxim Group | Buy | Maintained | $55.00 | +92.4% | 11/12/2026 |
Benjamin Burnett Wells Fargo | Buy | Maintained | $72.00 | +151.9% | 11/11/2026 |
Jay Olson Oppenheimer | Buy | Maintained | $75.00 | +162.4% | 11/10/2026 |
Ami Fadia Needham | Buy | Reiterated | $66.00 | +130.9% | 11/10/2026 |
Sumant Kulkarni Canaccord Genuity | Buy | Reiterated | $78.00 | +172.9% | 11/10/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $75.00 | +162.4% | 11/10/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $91.00 | +218.4% | 11/09/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $70.00 | +144.9% | 11/09/2026 |
Francois Brisebois LifeSci Capital | Buy | Maintained | $78.00 | +172.9% | 09/19/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | $67.00 | +134.4% | 09/15/2026 |
Christopher Chen Robert W. Baird | Buy | Maintained | $79.00 | +176.4% | 09/15/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $65.00 | +127.4% | 08/13/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $53.00 | +85.4% | 08/10/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $26.00 | -9% | 03/02/2026 |
Rudy Li Wolfe Research | Buy | Initiated | $25.00 | -12.5% | 02/23/2026 |
Last report
Nov 9, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.46 / -$0.56
+17.95%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 33.52M | 41.48M | 48.66M | 46.14M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 14.06M | 17.74M | 26.41M | 26.14M |
Operating expense | 47.58M | 59.22M | 75.08M | 72.28M |
Total operating expenses | 47.58M | 59.22M | 75.08M | 72.28M |
Operating income | -47.58M | -59.22M | -75.08M | -72.28M |
Other non operating income | -5.06M | -20.05M | -86.23M | 12.35M |
EBT including unusual items | -50.44M | -77.10M | -158.99M | -50.96M |
EBT excluding unusual items | -50.44M | -77.10M | -158.99M | -50.96M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -50.44M | -77.10M | -158.99M | -50.96M |
Net profit margin | - | - | - | - |
Earnings per share | - | - | -1.44 | -0.37 |
Interest and investment income | 3.49M | 3.46M | 3.59M | 10.14M |
Interest expense | -1.27M | -1.24M | -1.23M | -1.15M |
Net interest expenses | 2.22M | 2.21M | 2.35M | 8.99M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -47.57M | - | - | - |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events